This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Title of project or programme
| Title of PI | Donepezil and memantine in moderate to severe Alzheimer’s disease – The DOMINO-AD Trial |
Principal Investigators of project/programme grant
| Title | Forname | Surname | Institution | Country |
| Professor | Robert | Howard | King’s College London | UK |
Address of institution of lead PI
| Institution | King’s College London |
| Street Address | Strand |
| City | London |
| Postcode | WC2R 2LS |
Country
- United Kingdom
Source of funding information
Medical Research Council
Total sum awarded (Euro)
3369926.45
Start date of award
01-12-2006
Total duration of award in months
69
The project/programme is most relevant to
- Alzheimer’s disease and other dementias
Keywords
Research abstract in English
This RCT will examine efficacy of drug treatments for dementia (cholinesterase inhibitors and memantine), singly and in combination, over 12 months, in 800 Alzheimer s disease (AD)patients who are already treated with a cholinesterase inhibitor but have declined to reach the transition point to moderate to severe disease. Primary outcome measures will be cognitive function, activities of daily living and cost effectiveness. Secondary outcome measures will include quality of life, institutionalisation and family carer burden. The Trial has been designed to answer questions about the treatment of patients who are representative of those seen in clinical practice in terms of outcomes that have relevance to patients, carers and society.
Lay Summary
In which category does this research fall?
- Clinical research
Donepezil and memantine in moderate to severe Alzheimer’s disease – The DOMINO-AD Trial
Investments > €500k
United Kingdom
Alzheimer’s disease & other dementias
2011